Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of aminocamptothecin in treating patients who have
refractory or recurrent Hodgkin's disease or non-Hodgkin's lymphoma. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die.